Nigeria is set to launch the implementation of an €18 million grant from the European Union aimed at establishing a robust vaccine research and production ecosystem, marking a historic shift toward health sovereignty and reduced reliance on foreign supplies.

The initiative, led by the National Institute for Pharmaceutical Research and Development (NIPRD), supports the country’s first 10-Year National Plan for Vaccine Research, Development, and Local Production (2024–2034). It is the largest EU funding package for vaccine research on the continent to date.

NIPRD Director-General Dr. Obi Adigwe described the project as a watershed moment for Nigeria and Africa's broader vaccine autonomy.

“COVID-19 showed us the consequences of vaccine dependency. This program is not just about science; it’s about security, resilience, and dignity,” he stated.

During the pandemic, African nations were disproportionately affected by global vaccine shortages and hoarding, prompting calls for local manufacturing. The EU-backed initiative, developed in collaboration with Nigerian ministries, international partners, and private sector players, aims to fill that gap.

The plan includes the creation of vaccine research infrastructure, support for clinical trials, regulatory overhaul, technology transfer, and biopharma workforce development. It also envisions establishing three to four vaccine production companies in Nigeria over the next decade—anchoring the country as a regional hub for vaccine innovation.

“Execution is underway,” said Adigwe, noting that rollout teams have already been deployed to partners such as UNICEF.

The project aligns with the African Union’s 2040 goal of producing 60% of the continent’s vaccines locally. Currently, less than 1% are manufactured in Africa.

Experts have welcomed the initiative. Dr. Adaora Nwachukwu, a vaccine policy specialist, said the move could “reshape Africa’s vaccine landscape” if implemented effectively.

NIPRD will oversee coordination and ensure alignment with Nigeria’s broader health goals, including pandemic preparedness and manufacturing reforms.

“We’re not working in silos,” added Adigwe. “We invite collaboration from research institutions, startups, and global partners committed to health equity.”

For a nation of over 200 million people, local vaccine production isn’t just a scientific leap—it’s a strategic imperative.

 

Article by Nyokabi Wanjiku

Photo/Google

https://von.gov.ng/niprd-to-begin-eu-funded-vaccine-research-grant/